Mito BioPharm
Mito Biopharma is a biopharmaceutical company focusing on targeting mitochondria and cellular metabolism modulation to develop therapeutics for diseases such as NASH, type 2 diabetes, lipid disorders, neurodegenerative diseases, cancer, and aging. The company develops small molecule-based technology and lead compounds that aim to correct or modulate mitochondrial functions, with a focus on liver-based diseases and other metabolic disorders. It has a proprietary platform technology licensed from Rutgers University and is engaged in research, drug discovery, and development activities to address unmet medical needs in these areas.
Industries
Nr. of Employees
small (1-50)
Mito BioPharm
Piscataway, New Jersey, United States
Products
Lead small-molecule mitochondrial uncoupler candidates (IND-stage)
Selected small-molecule mitochondrial uncoupler candidates prioritized for liver-focused indications (NASH, type 2 diabetes) and validated preclinical leads for oncology indications (metastatic liver cancer, hematologic malignancies).
miunins
Small-molecule mitochondrial uncouplers developed by Mito Biopharma to mimic the physiological effects and functions of UCPs for treating metabolic, hepatic, and oncological diseases.
Lead compounds for NASH and Type 2 Diabetes
Proprietary small-molecule mitochondrial uncouplers designed to dissipate abnormal liver lipid accumulation by modulating mitochondrial function via safe uncoupling of mitochondrial respiration, targeting non-alcoholic steatohepatitis (NASH) and type 2 diabetes.
Mito Biopharma Small Molecule-Based Technology and Lead Compounds
Small molecule-based technology and lead compounds embodying the therapeutic strategy of correcting or modulating mitochondrial functions by increasing mitochondrial uncoupling to impact diseases such as NASH, type 2 diabetes, cancer, and neurodegenerative diseases.
MT-238
Selected as an IND lead for NASH and cancer indications, showing excellent pharmacology, ADME, PK/PD, and toxicology profiles.
MT-514
Selected as an IND lead for NASH and cancer indications, showing excellent pharmacology, ADME, PK/PD, and toxicology profiles.
Lead small-molecule mitochondrial uncoupler candidates (IND-stage)
Selected small-molecule mitochondrial uncoupler candidates prioritized for liver-focused indications (NASH, type 2 diabetes) and validated preclinical leads for oncology indications (metastatic liver cancer, hematologic malignancies).
miunins
Small-molecule mitochondrial uncouplers developed by Mito Biopharma to mimic the physiological effects and functions of UCPs for treating metabolic, hepatic, and oncological diseases.
Lead compounds for NASH and Type 2 Diabetes
Proprietary small-molecule mitochondrial uncouplers designed to dissipate abnormal liver lipid accumulation by modulating mitochondrial function via safe uncoupling of mitochondrial respiration, targeting non-alcoholic steatohepatitis (NASH) and type 2 diabetes.
Mito Biopharma Small Molecule-Based Technology and Lead Compounds
Small molecule-based technology and lead compounds embodying the therapeutic strategy of correcting or modulating mitochondrial functions by increasing mitochondrial uncoupling to impact diseases such as NASH, type 2 diabetes, cancer, and neurodegenerative diseases.
MT-238
Selected as an IND lead for NASH and cancer indications, showing excellent pharmacology, ADME, PK/PD, and toxicology profiles.
MT-514
Selected as an IND lead for NASH and cancer indications, showing excellent pharmacology, ADME, PK/PD, and toxicology profiles.
Services
Discovery and optimization of small-molecule mitochondrial modulators through SAR, synthesis, and lead selection workflows.
Conducting proof-of-concept efficacy studies in murine disease models to evaluate metabolic and oncology indications.
Preclinical ADME, PK/PD characterization and toxicology assessments to evaluate safety and therapeutic index of candidate compounds.
Management of patent filings and licensing of platform technology from an academic institution; engagement of external patent counsel.
Strategic partnering and licensing engagements planned at IND or later clinical phases to advance lead compounds with larger pharmaceutical partners.
Discovery and optimization of small-molecule mitochondrial modulators through SAR, synthesis, and lead selection workflows.
Conducting proof-of-concept efficacy studies in murine disease models to evaluate metabolic and oncology indications.
Preclinical ADME, PK/PD characterization and toxicology assessments to evaluate safety and therapeutic index of candidate compounds.
Management of patent filings and licensing of platform technology from an academic institution; engagement of external patent counsel.
Strategic partnering and licensing engagements planned at IND or later clinical phases to advance lead compounds with larger pharmaceutical partners.
Expertise Areas
- Drug discovery and medicinal chemistry
- Preclinical in vivo efficacy testing
- ADME/PK/PD characterization and toxicology
- Mitochondrial biology and metabolic modulation
Key Technologies
- Mitochondrial uncoupling small-molecule modulators
- Medicinal chemistry and SAR
- In vivo murine disease models (HFD, HFD+high-cholesterol, CCl4, db/db)
- ADME and PK/PD assays